European Network for Cancer research in Children and Adolescents (ENCCA)

Basic data for this project

Description

ENCCA aims to establish a durable, European Virtual Institute clinical and translational research in childhood and adolescent cancers that will define and implement an integrated research strategy and will facilitate the necessary investigator-driven clinical trials to introduce the new generation of biologically targeted drugs into standard of care for children and adolescents with cancer. This will lead to more efficacious and less toxic therapies that will maximise the quality of life of the increasing number of survivors of cancer at a young age in Europe and allow them to assume their proper place in society. This biologically-driven research agenda will improve training of the clinical investigators and translational scientists of the future to spread excellence, increase capacity to participate in research and monitor outcomes across Europe. Patients and their families will be full partners and will be better informed about the need for and processes of clinical research. They will be in a better situation to care from their long term health risks for children. Drug development will be accelerated in partnership with industry through improved access to young patients with cancer, to academic expertise in care, clinical and biological research. All of this will be achieved with respect for the highest ethical and patient safety standards. ENCCA will bring all stakeholders to the table in a timely and efficacious manner. It will address the needs of all the current multinational clinical trial groups for the benefit of children with cancer. It will provide them with common tools and approaches to solve the bottlenecks in testing new therapeutic strategies for those rare diseases in a vulnerable age group and in running a competitive clinical research agenda. Ongoing efforts to coordinate EU and US clinical research will be reinforced. ENCCA will be led by the most active EU institutes in the field (31), recognised as being at the forefront of excellence.